Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03580928

Recruitment Status : Active, not recruiting

First Posted : July 10, 2018

Last Update Posted : May 7, 2024

View this study on the modernized ClinicalTrials.gov

Sponsor:

Collaborators:

AstraZeneca

Genentech, Inc.

National Institutes of Health (NIH)

National Cancer Institute (NCI)

Information provided by (Responsible Party):

Matthew S. Davids, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Active, not recruiting
Actual Primary Completion Date :	April 10, 2024
Estimated Study Completion Date :	December 31, 2027

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Davids MS, Lampson BL, Tyekucheva S, Wang Z, Lowney JC, Pazienza S, Montegaard J, Patterson V, Weinstock M, Crombie JL, Ng SY, Kim AI, Jacobson CA, LaCasce AS, Armand P, Arnason JE, Fisher DC, Brown JR. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Lancet Oncol. 2021 Oct;22(10):1391-1402. doi: 10.1016/S1470-2045(21)00455-1. Epub 2021 Sep 14.

To Top